<DOC>
	<DOCNO>NCT01266408</DOCNO>
	<brief_summary>The study compare risk short- long-term use contraceptive contain drospirenone ( DRSP ) dienogest ( DNG ) /ethinylestradiol ( EE ) plus levomefolate calcium ( metafolin ) risk short- long-term use establish oral contraceptive ( OCs ) .</brief_summary>
	<brief_title>INAS-FOCUS ( International Active Surveillance Study - Folate Oral Contraceptives Utilization Study )</brief_title>
	<detailed_description>New oral contraceptive ( OCs ) contain drospirenone ( DRSP ) dienogest ( DNG ) /ethinylestradiol ( EE ) plus levomefolate calcium ( metafolin ) recently introduce introduced number country near future . Although safety OCs improve last 50 year reduction estrogen progestogen dose , special attention regard oral contraceptive safety amongst woman risk factor venous arterial thromboembolism well cancer necessary . Folic acid supplementation implicate prevention promotion several cancer , include colorectal cancer ( CRC ) . Chronic folate deficiency seem associate colorectal carcinogenesis , high folic acid level may tumor-promoting effect . On balance oral contraceptive contain folate may advantageous several reason . It may increase baseline folate level potential protect malignancy concurrently decrease risk neural tube defect woman become pregnant due OC-failure , incorrect OC-use stopping OC plan pregnancy . Although unexpected , unclear whether combined oral contraceptive plus metafolin general specifically DRSP/EE plus metafolin DNG/EE plus metafolin alter risk profile establish oral contraceptive . This study investigate safety new oral contraceptive regard cardiovascular outcome colorectal cancer . INAS-FOCUS prospective , control , non-interventional cohort study three study arm : user DRSP/EE/metafolin , user DNG/EE/metafolin user OCs contain estrogen/progestogen combination . The user group starter ( first-ever user ) , switcher ( woman switch OC without pill intake break ) restarters ( woman pill intake break ) . Users OC accrue network prescribe physician . Baseline follow-up information collect via self-administered questionnaire . Data analysis base life-table method compare cohort .</detailed_description>
	<mesh_term>Drospirenone</mesh_term>
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<criteria>Women start OC use ( `` starter '' ) Women switch OC use without pill intake break ( `` switcher '' ) Women restart OC use pill intake break ( `` restarters '' ) Women willing participate active surveillance Longterm user Women agree participate Women language barrier</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Drospirenone</keyword>
	<keyword>Dienogest</keyword>
	<keyword>Metafolin</keyword>
	<keyword>Folic acid</keyword>
	<keyword>Safety</keyword>
</DOC>